Honari Arvin, Sirsi Shashank R
Department of Bioengineering, Erik Johnson School of Engineering, The University of Texas at Dallas, Richardson, TX 75080, USA.
Pharmaceutics. 2023 Jun 10;15(6):1705. doi: 10.3390/pharmaceutics15061705.
Despite recent advancements in ultrasound-mediated drug delivery and the remarkable success observed in pre-clinical studies, no delivery platform utilizing ultrasound contrast agents has yet received FDA approval. The sonoporation effect was a game-changing discovery with a promising future in clinical settings. Various clinical trials are underway to assess sonoporation's efficacy in treating solid tumors; however, there are disagreements on its applicability to the broader population due to long-term safety issues. In this review, we first discuss how acoustic targeting of drugs gained importance in cancer pharmaceutics. Then, we discuss ultrasound-targeting strategies that have been less explored yet hold a promising future. We aim to shed light on recent innovations in ultrasound-based drug delivery including newer designs of ultrasound-sensitive particles specifically tailored for pharmaceutical usage.
尽管最近超声介导的药物递送取得了进展，并且在临床前研究中取得了显著成功，但尚未有利用超声造影剂的递送平台获得美国食品药品监督管理局（FDA）的批准。声孔效应是一项改变游戏规则的发现，在临床环境中有着广阔的前景。目前正在进行各种临床试验，以评估声孔效应在治疗实体瘤方面的疗效；然而，由于长期安全性问题，对于其在更广泛人群中的适用性存在分歧。在这篇综述中，我们首先讨论药物的声学靶向在癌症药物学中是如何变得重要的。然后，我们讨论了尚未得到充分探索但前景广阔的超声靶向策略。我们旨在阐明基于超声的药物递送的最新创新，包括专门为药物用途量身定制的新型超声敏感颗粒设计。
